International Retrospective Study on Pembrolizumab and Enfortumab Vedotin in Adults with Metastatic Urothelial Carcinoma
Led by Matteo Santoni · Updated on 2025-04-02
367
Participants Needed
1
Research Sites
195 weeks
Total Duration
AI-Summary
What This Trial Is About
This observational study focuses on patients with metastatic Urothelial Carcinoma UC who have been treated with specific therapies. It aims to retrospectively analyze patients who received pembrolizumab as first-line therapy if they were not suitable for platinum chemotherapy, or as second-line therapy after progression following platinum-based chemotherapy. The study also includes patients treated with enfortumab vedotin after progression following platinum chemotherapy and anti-PD-1PD-L1 inhibitors. These analyses help understand treatment outcomes in this patient group.
The study examines patients who received at least one cycle of pembrolizumab between January 1, 2018, and November 30, 2021, or at least one cycle of enfortumab vedotin between June 1, 2022, and July 31, 2023. Both treatments are evaluated based on their prior use following platinum-based chemotherapy and progression status. The study does not involve new treatments but reviews patient records to assess outcomes related to these therapies.
Participants clinical data will be reviewed to measure overall survival, progression-free survival, and overall response rate to pembrolizumab or enfortumab vedotin. Secondary analysis includes the impact of smoking habits, obesity, and other medications on treatment outcomes. The study involves no active intervention and lasts until September 30, 2027, with data collected retrospectively to better understand treatment effectiveness and patient prognostic factors.
CONDITIONS
Brief Title
ARON-2 Study-Multicentric International Retrospective Study
Research Team
M
Matteo Santoni, MD, PhD
G
Giulia Sorgentoni
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histologically confirmed diagnosis of urothelial carcinoma of upper and/or lower urinary tract
Histologically or radiologically confirmed metastatic disease
Patients treated with pembrolizumab after platinum-based chemotherapy or as first-line if platinum-unfit, with at least one cycle between January 2018 and November 2021
Patients treated with enfortumab vedotin after platinum-based chemotherapy and anti-PD-1/PD-L1 inhibitor, with at least one cycle between June 2022 and July 2023
You will not qualify if you...
Patients without histologically confirmed diagnosis of urothelial carcinoma
Patients without histologically or radiologically confirmed metastatic disease
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Monitoring
Duration - Until study completion on September 30, 2027
Participants who have received specified treatments for metastatic urothelial carcinoma are observed to assess overall survival, progression-free survival, and response rates.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Phase II Study Comparing 9MW2821 with and without Toripalimab for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Phase II Study of 9MW2821 and Toripalimab Infusions for Perioperative Treatment of Urothelial Cancer
Phase 3 Study Comparing 9MW2821 with Toripalimab to Standard Chemotherapy for First Treatment of Advanced or Metastatic Urothelial Cancer
Open-Label Phase 1 Trial Evaluating Safety and Activity of HH160 Alone or With Other Cancer Treatments in Adults With Advanced or Metastatic Solid Tumors
Get Moving Trial Evaluating Home-Based Prehabilitation Exercise Using ExerciseRx App
for Bladder and Upper Tract Urothelial Cancer Patients Undergoing Surgery
Study on Using Pre-treatment Tumor Biopsies to Predict Response to PD-1PD-L1 Immunotherapy in Various Cancers
Phase 2 Study of ABSK061 and ABSK043 to Treat Metastatic or Unresectable Solid Tumors with FGFR23 Alterations, With or Without Chemotherapy
Open-label Phase 2 Study Evaluating Zanidatamab for Previously Treated HER2-expressing Solid Tumors
Phase 3 Study of UGN-104 Instillation for Treatment of Low-grade Upper Tract Urothelial Cancer
Phase II Study of BL-B01D1 Plus PD-1 Therapy for Adults With Advanced or Metastatic Urothelial Carcinoma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).
Veronica Mollica, Francesco Massari, Kazutoshi Fujita...
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience.